UNC0.F UCB S.A. UNSP.ADR 1/2
- Market cap
- EUR 55.2B
- P/E
- 25.6x
- P/B
- 4.84x
- ROE
- 14.3%
- Dividend yield
- 0.48%
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is UNC0.F undervalued?
Graham numberUNC0.F trades 134.6% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
UCB S.A. UNSP.ADR 1/2 fundamental analysis
No fundamental analysis for UCB S.A. UNSP.ADR 1/2 yet.
UCB S.A. UNSP.ADR 1/2 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About UCB S.A. UNSP.ADR 1/2
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs …
Full company profileUCB S.A. UNSP.ADR 1/2 financial statements
UCB S.A. UNSP.ADR 1/2 annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 5.78B | 5.52B | 5.25B | 6.15B | 7.74B |
| Gross Profit | 4.34B | 3.84B | 3.55B | 4.40B | 5.75B |
| Operating Income | 1.32B | 701M | 633M | 846M | 2.00B |
| EBITDA | - | 1.17B | 1.28B | 1.96B | 2.58B |
| Net Income | 1.06B | 418M | 343M | 1.07B | 1.56B |
| EPS | 5.59 | 2.20 | 1.81 | 5.60 | 8.18 |
| Balance Sheet | |||||
| Total Assets | 14.2B | 15.9B | 15.5B | 17.3B | 18.2B |
| Total Liabilities | 5.82B | 6.80B | 6.56B | 7.32B | 7.29B |
| Shareholders' Equity | 8.39B | 9.06B | 8.98B | 10.0B | 10.9B |
| Cash & Short-term Investments | 1.26B | 899M | 861M | 1.57B | 2.25B |
| Cash Flow | |||||
| Operating Cash Flow | 1.55B | 1.12B | 761M | 1.24B | 2.29B |
| Capital Expenditure | 493M | 371M | 316M | 322M | 449M |
| Free Cash Flow | 1.06B | 748M | 445M | 920M | 1.84B |
| Ratios | |||||
| ROE | 12.6% | 4.6% | 3.8% | 10.6% | 14.3% |
| ROA | 7.4% | 2.6% | 2.2% | 6.1% | 8.6% |
| Net Profit Margin | 18.3% | 7.6% | 6.5% | 17.3% | 20.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
UCB S.A. UNSP.ADR 1/2 dividends
- Dividend yield
- 0.48%
- Forward dividend
- 0.73 EUR
- Payout ratio
- 16.9%
- Ex-dividend date
- May 5, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | EUR 264M | 1.39 | 16.9% |
| 2024 | EUR 259M | 1.36 | 24.3% |
| 2023 | EUR 252M | 1.33 | 73.5% |
| 2022 | EUR 247M | 1.30 | 59.1% |
| 2021 | EUR 240M | 1.27 | 22.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns UCB S.A. UNSP.ADR 1/2
- Insiders 0.00%
- Institutions 0.02%
- Public & others 99.98%
- Shares outstanding 381M
- Free float 240M
UCB S.A. UNSP.ADR 1/2 company profile
- Company name
- UCB S.A. UNSP.ADR 1/2
- Ticker
- UNC0.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 9,000
- Fiscal year end
- December
- Address
- Allée de la Recherche, 60, Brussels, Belgium, 1070
- Phone
- 32 2 559 99 99
- Website
- ucb.com
About UCB S.A. UNSP.ADR 1/2
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. In addition, the company offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx to treat plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; Fintepla for the treatment of Dravet and Lennox-Gastaut syndrome; and RYSTIGGO and ZILBRYSQ to treat people living with generalized myasthenia gravis. Further, it develops KYGEVVI (doxecitine/doxribtimine) for thymidine kinase 2 deficiency disorder; fenfluramine to treat CDKL5 deficiency disorder, and RETT-Syndrome; dapirolizumab pegol for systemic lupus erythematosus; STACCATO alprazolam for treating stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; and UCB9741 for atopic dermatitis, non cystic fibrosis bronchiectasis, and chronic obstructive pulmonary disease. Additionally, it engages in the contract manufacturing activities. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
UCB S.A. UNSP.ADR 1/2 management
10- Dr. Jean-Christophe TellierCEO & Executive Director · born 1959
- Ms. Sandrine Dufour CFAExecutive VP & CFO · born 1966
- Mr. Alistair HenryExecutive VP & Chief Scientific Officer · born 1967
- Ms. Denelle J. Waynick Johnson J.D.Executive VP & General Counsel · born 1967
- Mr. Jean-Luc FleurialExecutive VP & Chief Human Resources Officer · born 1965
- Mr. Emmanuel CaeymaexExecutive VP & Head of Patient Evidence · born 1969
- Ms. Fiona Du MonceauExecutive VP of Patient Impact & Chief Commercial Officer · born 1978
- Ms. Caroline VancoillieChief Accounting Officer & Head of Group Finance
- Gwendoline OrniggHead of Global Corporate Communication
- Veronique ToullyHead of Sustainability, Corporate Affairs & Enterprise Risk Management